HRS9531 Phase 3 Study, ASCVD, MACE Endpoint
Summary
A Phase 3 clinical trial (NCT07551492) for HRS9531 has been registered on ClinicalTrials.gov. The study will evaluate the efficacy and safety of HRS9531 on major adverse cardiovascular events (MACE) in participants with atherosclerotic cardiovascular disease. The trial uses an event-driven design, ending when the target number of primary endpoint events is reached. Conditions include Atherosclerotic Cardiovascular Disease; interventions are HRS9531 and HRS9531 placebo.
“The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new Phase 3 clinical trial has been registered for HRS9531, an investigational product, in participants with atherosclerotic cardiovascular disease. The trial's primary endpoint is major adverse cardiovascular events (MACE). The study adopts an event-driven design, meaning it will conclude once sufficient primary endpoint events have been observed to enable statistical analysis.
For pharmaceutical manufacturers and clinical research organizations, this registry entry signals active late-stage development of HRS9531 for a cardiovascular indication. Sponsors with competing cardiovascular programs should monitor enrollment status and trial results, as positive outcomes could affect competitive positioning in the ASCVD treatment landscape.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
Phase 3 NCT07551492 Kind: PHASE3 Apr 24, 2026
Abstract
The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.
Conditions: Atherosclerotic Cardiovascular Disease
Interventions: HRS9531, HRS9531 placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.